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ABSTRACT 
Background: The evidence on the prognostic value of transthoracic 
echocardiography (TTE) in elderly, hemodynamically stable patients with pulmonary 
embolism (PE) is limited. 
Objectives: To evaluate the prevalence of common echocardiographic signs of right 
ventricular (RV) dysfunction and their prognostic impact in hemodynamically stable 
patients aged ≥65 years with acute PE in a prospective multicenter cohort. 
Methods: TTE was performed by cardiologists. We defined RV dysfunction as a 
RV/left ventricular ratio >0.9 or RV hypokinesis (primary definition) or the presence of 
≥1 or ≥2 of 6 predefined echocardiographic signs (secondary definitions). Outcomes 
were overall mortality and mortality/non-fatal recurrent venous thromboembolism 
(VTE) at 30 days, adjusting for the Pulmonary Embolism Severity Index risk score 
and highly sensitive troponin T values. 
Results: Of 400 patients, 36% had RV dysfunction based on our primary definition, 
and 81% (≥1 sign) and 53% (≥2 signs) based on our secondary definitions, 
respectively. Using our primary definition, there was no association between RV 
dysfunction and mortality (adjusted HR 0.90, 95% CI 0.31-2.58) and mortality/non-
fatal VTE (adjusted HR 1.09, 95% CI 0.40-2.98). Similarly, there was no statistically 
significant association between the presence of ≥1 or ≥2 echocardiographic signs 
(secondary definitions) and clinical outcomes. 
Conclusion: The prevalence of echocardiographic RV dysfunction varied widely 
depending upon the definition used. There was no association between RV 
dysfunction and clinical outcomes. Thus, TTE may not be suitable as a stand-alone 
risk assessment tool in elderly patients with acute PE. 
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Clinical Trial Registration: http://clinicaltrials.gov. Identifier: NCT00973596. 
 
Keywords: echocardiography, pulmonary embolism, mortality 
  
 
5 
INTRODUCTION 
Evidence suggests that echocardiographic signs of right ventricular (RV) 
dysfunction or pulmonary hypertension (hereafter called signs of RV dysfunction) are 
associated with a 2-fold increase in short-term overall mortality in hemodynamically 
stable patients with acute pulmonary embolism (PE) [1, 2]. Several professional 
societies have therefore incorporated transthoracic echocardiography (TTE), alone or 
in combination with cardiac biomarkers, into their risk assessment strategies for 
hemodynamically stable patients with acute PE [3, 4]. According to current 
recommendations, fibrinolysis may be considered in selected hemodynamically 
stable patients with RV dysfunction [3, 4]. TTE has been widely adopted into clinical 
practice and despite its costs and the need for a trained physician, currently more 
than a third of patients diagnosed with acute PE undergo TTE [5, 6]. 
Although elderly patients have more severe venous thromboembolism (VTE) 
and a higher short-term mortality rate than younger patients [7, 8], the prognostic 
performance of TTE to predict mortality has not been specifically examined in elderly 
patients with acute PE. The aim of this study was to prospectively evaluate the 
prevalence of common echocardiographic signs of RV dysfunction and their 
prognostic impact in elderly patients with acute PE. 
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METHODS 
Cohort sample 
This study was conducted between September 2009 and June 2012 as part of 
a prospective, multicenter cohort study to assess long-term medical outcomes and 
quality of life in patients aged ≥65 years with an acute VTE from all five Swiss 
university and four high-volume non-university hospitals [9]. Consecutive patients 
aged ≥65 years with an acute VTE were identified in the inpatient and outpatient 
services of all participating study sites. Exclusion criteria were catheter-related 
thrombosis, insufficient German or French-speaking ability, no follow-up possible 
(i.e., terminal illness), an inability to provide informed consent (i.e., severe dementia), 
or previous enrollment in the cohort. The study was approved by the Institutional 
Review Board at each participating center. The detailed study methods were 
previously published [9]. For the present study, we only considered hemodynamically 
stable patients with an acute symptomatic, objectively confirmed PE [9]. 
Hemodynamic stability was defined as a systolic blood pressure of ≥90 mm Hg at the 
time of PE diagnosis. 
 
Baseline data collection 
Trained study nurses prospectively collected baseline demographic 
characteristics, comorbid conditions, type of PE (unprovoked vs. provoked), 
localization of PE, vital signs, routine laboratory findings (hemoglobin, serum 
creatinine), and anticoagulation-related treatments. In addition, we recorded whether 
the patient was admitted to the intensive care unit or received intravenous 
catecholamines, cardiopulmonary resuscitation, vena cava filter, fibrinolysis, or 
thromboembolectomy in the hospital. 
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We also collected venous blood samples at the time of PE diagnosis. Samples 
were immediately centrifuged, frozen, and stored at -80°C and sent for analyses to a 
core laboratory. Plasma concentrations of N-terminal pro-brain natriuretic peptide 
(NT-proBNP) and highly sensitive troponin T (hsTnT) were measured quantitatively 
using a Cobas e601 automated immunoanalyser (electrochemiluminescence 
methods, Hoffmann-La Roche, Rotkreuz, Switzerland). 
 
Echocardiographic examination 
Patients underwent TTE at the time of study enrollment to assess RV function. 
All TTEs were performed by on-site cardiologists according to a standardized 
protocol. The cardiologists were blinded to patients’ baseline characteristics and 
treatments. The following six signs of RV dysfunction/pulmonary hypertension were 
recorded: 1) RV/LV end-diastolic diameter ratio >0.9 in the apical four chamber view, 
2) RV hypokinesis (defined as a moderately or severely abnormal motion of RV free 
wall), 3) paradoxical septal motion, 4) decreased or absent inspiratory collapse of the 
inferior vena cava, 5) shortened pulmonary acceleration time in the parasternal short 
axis view (≤100 ms), and 6) increase in RV/right atrial gradient in the apical four 
chamber or parasternal short axis view (≥30 mm Hg) [10-14]. For the present 
analysis, we considered only patients who had TTE within three days of PE diagnosis 
[15]. 
We used the presence of a RV/LV ratio >0.9 or RV hypokinesis as our primary 
definition of RV dysfunction, as suggested by the American Heart Association [3]. 
However, because the definition of RV dysfunction varies widely across studies, we 
also defined RV dysfunction as the presence of at least one and at least two of six 
echocardiographic signs described above, respectively (secondary definitions). 
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Study outcomes 
The primary outcome was overall mortality within 30 days of PE diagnosis. 
The secondary outcome was overall mortality/non-fatal recurrent VTE at 30 days. 
Recurrent VTE was defined as symptomatic, objectively confirmed recurrent PE or a 
new symptomatic deep vein thrombosis [9]. Follow-up included a face-to-face patient 
interview and hospital chart review at 90 days, complemented by proxy interviews 
and an interview of the patient’s primary care physician. A committee of three blinded 
clinical experts adjudicated all outcomes and classified the cause of all deaths as 
definitely due to PE, possibly due to PE, or due to another cause [9]. Final 
classifications were made on the basis of the full consensus of this committee. 
 
Statistical analysis 
We compared baseline characteristics and descriptive outcome data of 
patients with and without RV dysfunction using the Fisher’s exact test for categorical 
data and the Wilcoxon rank-sum test for continuous variables as appropriate. In 
patients treated with vitamin K antagonists, we compared the percentage of time 
spent in the therapeutic INR range (2.0-3.0) using analysis of variance [16]. We used 
Kaplan-Meier curves and the log-rank test to compare the cumulative overall 
mortality and overall mortality/recurrence of non-fatal VTE within 30 days in patients 
with and without RV dysfunction. 
We examined the association between RV dysfunction and clinical outcomes 
using a Cox-regression model. We adjusted all models for the Pulmonary Embolism 
Severity Index risk score and hsTnT. The Pulmonary Embolism Severity Index is a 
validated prognostic score and comprises 11 clinical variables, including 
demographics (age, gender), comorbid diseases (cancer, heart failure, and chronic 
lung disease), and vital signs (altered mental status, pulse, systolic blood pressure, 
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respiratory rate, arterial oxygen saturation, and temperature) [17]. Given that NT-
proBNP is another marker for RV dysfunction, we did not adjust for this parameter 
[18]. Because RV dysfunction may be transitory, we also examined the association 
between RV dysfunction and clinical outcomes in the subgroup of patients who had 
TTE within one day of PE diagnosis [19]. Missing values in covariates used for 
adjustment were assumed as normal. We considered P-values <0.05 to be 
statistically significant. All analyses were performed using Stata 14.0.  
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RESULTS 
Study sample 
Overall, 685 hemodynamically stable patients with PE were initially enrolled in 
our study. After exclusion of 285 (42%) patients (277 had no TTE within three days 
and 8 withdrew consent early or did not allow use of their data), our final sample 
comprised 400 patients. Excluded patients were more likely to be women (53% vs. 
44%, P=0.02) and to have hospital-acquired PE (22% vs. 14%, P=0.007) or anemia 
(43% vs. 35%, P=0.029) than analyzed patients. The other baseline characteristics, 
including illness severity based on the Pulmonary Embolism Severity Index, were 
comparable. There were no differences in mortality, intensive care admission, 
catecholamine use, fibrinolysis, cardiopulmonary resuscitation, or 
thromboembolectomy (data not shown). 
Patients with RV dysfunction based on our primary definition were older and 
were more likely to have a history of VTE, unprovoked, central, or lobar PE, a heart 
rate ≥110/minute, a respiratory rate ≥30/minute, and an arterial oxygen saturation 
<90% than patients without RV dysfunction (Table 1). Patients with RV dysfunction 
had also a higher proportion of NT-proBNP >500 pg/ml, and were more likely to be 
admitted to the intensive care unit, receive fibrinolysis, and have cardiopulmonary 
resuscitation than patients without RV dysfunction. In patients treated with vitamin K 
antagonists, the percentage of time in the therapeutic range did not vary between 
patients with and without RV dysfunction (61% vs. 63%, P=0.37). 
The prevalence of echocardiographic signs of RV dysfunction varied from 15% 
for RV hypokinesis to 54% for pulmonary acceleration time ≤100 ms (Table 2). 
Overall, 36% of patients had a RV/LV end-diastolic diameter ratio >0.9 or RV 
hypokinesis (primary definition), and 81% and 53% had ≥1 and ≥2 signs of RV 
dysfunction, respectively (secondary definitions). 
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Comparison of outcomes 
Fifteen patients (3.8%) died within 30 days of the index PE. Of these, 5 died 
from definite/possible PE, 3 from cancer, 1 from left ventricular heart failure, 1 from 
other pulmonary causes, 2 from bleeding, 2 from sepsis, and 1 from an unknown 
cause. One patient (0.3%) had recurrent non-fatal VTE. Only 3 patients (0.8%) died 
within 7 days, all from definite/possible PE. Patients with RV dysfunction based on 
our primary definition had the same cumulative incidence of overall mortality and 
mortality/recurrence of non-fatal VTE than patients without RV dysfunction (Figure 1, 
Panel A and B). Based on our primary definition, the 30-day overall mortality was 
4.2% and 3.5% for patients with and without RV dysfunction, respectively (P=0.79), 
with no difference in definite/possible fatal PEs (2.1% vs. 0.8%; P=0.35). Using the 
presence of ≥1 and ≥2 echocardiographic signs to define RV dysfunction, the overall 
mortality was 4.3% vs. 1.3% (P=0.32) and 4.7% vs. 2.7% (P=0.43), respectively. 
 
Association between RV dysfunction and clinical outcomes 
RV dysfunction based on our primary definition was not associated with overall 
mortality (adjusted hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.31-2.58) 
and the combined outcome of overall mortality/recurrence of non-fatal VTE within 30 
days (HR 1.09, 95% CI 0.40-2.98) (Table 3). Using secondary definitions of RV 
dysfunction, patients with RV dysfunction were somewhat more likely to experience 
death or death/non-fatal recurrence of VTE than patients without RV dysfunction but 
the association did not reach statistical significance (Table 3). When we restricted the 
analysis to the 189 patients (47%) who had TTE within one day of PE diagnosis, the 
results did not change markedly (results not shown). 
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DISCUSSION 
In our prospective cohort study, we found no significant association between 
echocardiographic signs of RV dysfunction and clinical outcomes in hemodynamically 
stable elderly patients with acute PE, irrespective of the definition used. Depending 
on the definition of RV dysfunction, the prevalence of RV dysfunction varied widely 
and ranged from 36% using a restrictive (RV/LV end-diastolic diameter ratio >0.9 or 
RV hypokinesis) to 81% using a broader definition (presence of ≥1 echocardiographic 
sign). Our findings are consistent with results from prior studies in which the 
prevalence of echocardiographic RV dysfunction varied greatly from 20% to 68% in 
hemodynamically stable patients with PE [20, 21]. This substantial heterogeneity in 
the prevalence has been attributed to the lack of standardization of criteria used to 
define RV dysfunction and differences in patient characteristics [22]. Moreover, inter-
observer reliability of echocardiographic signs of RV dysfunction in hemodynamically 
stable patients with PE appears to be heterogenous, the agreement between 
cardiologists varying from fair (κ=0.45) for RV end-diastolic diameter measurement to 
good for RV hypokinesis (κ=0.70) [23]. A future effort to establish more standardized, 
reliable criteria of RV function is needed. 
In contrast to the majority of studies enrolling younger hemodynamically stable 
patients with PE [13, 15, 20, 21, 24-30], we did not find a relationship between 
echocardiographic RV dysfunction and short-term clinical outcomes in our sample of 
elderly patients. In particular, the specific set of echocardiographic criteria 
recommended by the American Heart Association (presence of RV/LV end-diastolic 
diameter ratio >0.9 or RV hypokinesis) was not associated with adverse clinical 
events. There are several potential explanations for our results. First, only 33% of 
patients who died during follow-up died from definite/possible PE, indicating that 
short-term prognosis of elderly patients with acute PE may be more often driven by 
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comorbidities than by PE-related RV dysfunction. RV dysfunction may also reflect 
cardiac and pulmonary diseases rather than severity of PE in the elderly [31, 32]. 
Mortality from definite/possible PE did not differ by RV function in our study. 
Second, patients with RV dysfunction were more likely to be admitted to the 
intensive care unit and to receive fibrinolysis than patients without RV dysfunction, 
which may have improved an otherwise poor prognosis. However, this scenario 
seems unlikely in light of the results of the PEITHO trial [33]. While fibrinolysis 
reduced the risk of decompensation in hemodynamically stable patients with PE who 
had RV dysfunction and elevated troponin in this trial, overall mortality did not differ, 
and the risk-benefit ratio of fibrinolysis was worse in patients aged >75 years [34]. 
Finally, although TTEs were performed according to a standardized protocol, 
readings were not centrally adjudicated and we have no information about reliability 
and technical quality of the exams. Although this may be a limitation, the quality of 
our TTEs is likely to be representative of the real world situation in many hospitals. 
In a scientific statement, the American Heart Association recommends 
fibrinolysis as a treatment option for hemodynamically stable patients with PE who 
have evidence of moderate to severe RV strain [3]. According to the European 
Society of Cardiology, patients with stable PE who have both signs of RV dysfunction 
on TTE and elevated troponin should be closely monitored for clinical deterioration 
[4]. Our findings do not support the use of TTE in the risk stratification of elderly 
patients with PE, at least not as a stand-alone risk assessment tool. In a prior study, 
the use of TTE to risk-stratify patients with PE resulted in higher care levels and more 
advanced treatments but did not improve outcomes [6]. 
Our study has several potential limitations. First, we excluded 42% of patients, 
mostly, because TTE was not available within three days of PE diagnosis. However, 
excluded patients did not appear to be more severely ill or to have more adverse 
 
14 
outcomes than analyzed patients, making a selection bias unlikely. Second, because 
PE-related RV dysfunction may be transient and only about half of patients had TTE 
within one day of PE diagnosis, we may have not captured all patients with initial RV 
dysfunction. However, when restricting our analysis to patients who had TTE within 
one day of PE diagnosis, the results did not change. Third, we did not evaluate 
hemodynamic (PE-related) decompensation, we only collected information regarding 
PE-related processes of care (e.g., fibrinolysis, intensive care unit admission, 
administration of catecholamines, and cardiopulmonary resuscitation). However, 
managing physicians were not blinded to RV function and the utilization of these 
treatments may have been partially influenced by managing physicians’ knowledge of 
patients’ RV function. Thus, the use of these treatments may at least partially reflect 
guideline or expert recommendations and not the occurrence of hemodynamic 
decompensation. Fourth, as a predefined ancillary study within the SWITCO65+ 
prospective cohort, our study was not powered to detect mortality differences 
between patients with and without RV dysfunction. Specifically, there were not 
enough PE-related deaths to examine the association between RV dysfunction and 
PE-related mortality. Finally, our results may not be generalizable to more novel 
echocardiographic signs that were not examined in our study (e.g., tricuspid annular 
plane systolic excursion [TAPSE]) [35]. 
In conclusion, the prevalence of echocardiographic RV dysfunction varies 
widely based on the criteria used to define RV dysfunction in elderly, 
hemodynamically stable patients with acute PE. We did not find an association 
between RV dysfunction and short-term clinical outcomes. Our results do not support 
TTE as a stand-alone risk stratification tool in the elderly with acute PE.  
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FIGURE LEGENDS 
Figure 1 
Panel A. Kaplan-Meier estimates of overall mortality by RV function* 
The cumulative incidence of overall mortality at 30 days was 4.2% for patients with 
RV dysfunction vs. 3.5% for patients without RV dysfunction (P=0.728) by the log-
rank test). 
 
Panel B. Kaplan-Meier estimates of overall mortality or recurrence of non-fatal 
venous thromboembolism by RV function* 
The cumulative incidence of the combined outcome of overall mortality and 
recurrence of non-fatal venous thromboembolism at 30 days was 4.9% for patients 
with RV dysfunction vs. 3.5% for patients without RV dysfunction (P=0.501) by the 
log-rank test). 
Abbreviations: RV= right ventricular. 
*RV dysfunction was defined as the presence of a RV/left ventricular end-diastolic diameter ratio >0.9 
or a right ventricular hypokinesis on transthoracic echocardiography. 
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Table 1.  Patient baseline characteristics by echocardiographic RV function 
 RV dysfunction* 
(N=143) 
No RV dysfunction 
(N=257) 
P-
value 
 n (%) or median (IQR)† 
 
 
Age, years 75.0 (70.0-84.0) 74.0 (69.0-80.0) 0.041 
Male gender      78 (55)        147 (57)    0.674  
Active cancer‡      17 (12)         49 (19)     0.069  
Heart failure§      21 (15)         25 (10)     0.144 
Chronic lung disease‖      19 (13)         38 (15)     0.766  
Prior history of VTE      49 (34)         62 (24)     0.036  
Unprovoked index PE¶     114 (80)        177 (69)     0.020  
Localization of PE#    
Central      62 (43)         73 (28)     0.003  
Lobar      73 (51)         98 (38)     0.015  
Segmental      93 (65)        179 (70)     0.372  
Subsegmental      41 (29)        107 (42)     0.013  
Isolated subsegmental       5 (3)         28 (11)     0.013  
Unknown localization       9 (6)          9 (4)     0.214  
Altered mental status       6 (4)         11 (4)     1.000  
Heart rate ≥110 beats/minute      27 (19)         23 (9)     0.007  
Systolic blood pressure <100 mm Hg        4 (3)       4 (2)    0.464 
Temperature <36 C°      11 (8)         26 (10)     0.588  
Respiratory rate ≥30 breaths/minute      11 (8)          5 (2)     0.017  
Arterial oxygen saturation <90%      31 (22)         28 (11)     0.005  
PESI risk class    0.414  
I       1 (1)          4 (2)      
II      37 (26)         85 (33)      
III      48 (34)         81 (31)      
IV      35 (24)         60 (23)      
V      22 (15)         27 (11)      
Anemia††      41 (29)         98 (38)     0.062  
Serum creatinine >1.5 mg/dl      11 (8)         29 (11)     0.299  
Highly sensitive troponin T >0.1 ng/ml      13 (9)         11 (4)     0.082  
NT-proBNP >500 pg/ml      91 (64)         93 (36)    <0.001  
VKA therapy prior to PE diagnosis       8 (6)          7 (3)     0.173  
Initial parenteral anticoagulation    0.048  
Low molecular weight heparin       55 (39)      132 (51)      
Unfractionated Heparin       65 (46)         84 (33)      
Fondaparinux      21 (15)         35 (14)      
No parenteral anticoagulation       2 (1)          6 (2)      
Subsequent VKA therapy     133 (93)        231 (90)     0.363  
 
Continued 
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Continued 
 RV dysfunction* 
(N=143) 
No RV dysfunction 
(N=257) 
P-
value 
 n (%) or median (IQR)† 
 
 
Use of inferior vena cava filter 2 (1) 1 (1) 0.292 
Admission to intensive care unit 25 (18) 22 (9)  0.010  
Use of intravenous 
catecholamines‡‡ 3 (2) 4 (2)  0.704  
Cardiopulmonary resuscitation 3 (2) 0 (0)  0.045  
Fibrinolysis§§ 11 (8) 4 (2)  0.004  
Thromboembolectomy‖‖ 0 (0) 1 (1)  1.000  
 
Abbreviations: RV= right ventricular; IQR= interquartile range; VTE= venous thromboembolism. PESI= 
Pulmonary Embolism Severity Index; PE= pulmonary embolism; VKA= vitamin K antagonist. 
*RV/left ventricular end-diastolic diameter ratio >0.9 or RV hypokinesis. 
†Data were missing for heart rate (1%), systolic blood pressure (1%), temperature (3%), respiratory 
rate (21%), arterial oxygen saturation (5%), anemia (1%), creatinine (2%), hsTNT (11%), and NT-
proBNP (11%). 
‡Cancer requiring surgery, chemotherapy, radiotherapy, or palliative care during the last 3 months. 
§Acute heart failure NYHA class II-IV during the last 3 months, history of systolic/diastolic heart failure, 
left/right heart failure, forward/backward heart failure, or left ventricular ejection fraction of <40%. 
‖Chronic obstructive pulmonary disease, active asthma, lung fibrosis, cystic fibrosis, or 
bronchiectasies. 
#Absence of major surgery, estrogen therapy, or immobilization (fracture or cast of the lower 
extremity, bed rest >72 hours, or voyage in sitting position for >6 hours) during the last 3 months. 
#Multiple localizations per patient were possible. 
††Hemoglobin <130 g/l for men and <120 g/l for women. 
‡‡Dopamin, dobutamin, adrenalin, noradrenalin, or vasopressin. 
§§Systemic or catheter-based fibrinolysis. 
‖‖Catheter-based or surgical thromboembolectomy. 
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Table 2.  Prevalence of echocardiographic signs of RV dysfunction (N=400) 
Echocardiographic sign n (%)* 
RV/LV end-diastolic diameter ratio >0.9  124 (31) 
RV hypokinesis   58 (15) 
Paradoxical septal motion   82 (21) 
Reduced inspiratory collapse of the inferior vena cava  109 (27) 
Pulmonary acceleration time ≤100 ms  216 (54) 
RV/right atrial gradient ≥30 mm Hg  193 (48) 
Presence of RV/LV end-diastolic diameter ratio >0.9 or 
RV hypokinesis  143 (36) 
Presence of ≥1 sign of RV dysfunction  324 (81) 
Presence of ≥2 signs of RV dysfunction  213 (53) 
 
Abbreviations: RV= right ventricular; LV= left ventricular. 
*6% of patients had missing values for RV/LV ratio, 2% for RV hypokinesis, 3% for paradoxical septal 
motion, 11% for inspiratory collapse of the inferior vena cava, 22% for pulmonary acceleration time, 
and 23% for RV/right atrial gradient. 
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Table 3.  Association between echocardiographic RV dysfunction and clinical 
outcomes within 30 days 
 Adjusted hazard ratio* 
(95% confidence interval) 
RV/LV ratio >0.9 or RV hypokinesis  
Overall mortality 0.90 (0.31-2.58) 
Overall mortality or recurrence of non-fatal VTE 1.09 (0.40-2.98) 
Presence of ≥1 sign of RV dysfunction†  
Overall mortality 2.22 (0.28-17.42) 
Overall mortality or recurrence of non-fatal VTE 2.52 (0.32-19.57) 
Presence of ≥2 signs of RV dysfunction†  
Overall mortality 1.43 (0.48-4.20) 
Overall mortality or recurrence of non-fatal VTE 1.60 (0.55-4.64) 
 
Abbreviations: RV= right ventricular, LV= left ventricular, VTE= venous thromboembolism. 
*Adjusted for Pulmonary Embolism (PE) Severity Index risk score and hsTnT >0.1 ng/ml. 
†RV/LV end-diastolic diameter ratio >0.9 in the apical four chamber view, RV hypokinesis, paradoxical septal 
motion, decreased or absent inspiratory collapse of the inferior vena cava, decrease in pulmonary 
acceleration time in the parasternal short axis view (≤100 ms), or increase in RV/right atrial gradient in the 
apical four chamber or parasternal short axis view (≥30 mm Hg). 
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Figure. 
A. 
 
B. 
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